Quick Answer
ImmunityBio, Inc. reported Net Income of -$351.40 million for fiscal year 2025.
ImmunityBio, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$351.40M | +15.0% |
| 2024 | -$413.56M | +29.1% |
| 2023 | -$583.20M | -40.0% |
| 2022 | -$416.57M | -20.1% |
| 2021 | -$346.79M | -56.3% |
| 2020 | -$221.85M | -40.6% |
| 2019 | -$157.78M | -64.0% |
| 2018 | -$96.23M | +0.2% |
| 2017 | -$96.42M | +20.2% |
| 2016 | -$120.81M | +49.0% |
| 2015 | -$236.88M | -3729.8% |
| 2014 | -$6.18M | -202.1% |
| 2013 | -$2.05M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$67.25M | +21.6% | +27.3% |
| June 30, 2025 | -$92.56M | +31.2% | +28.6% |
| March 31, 2025 | -$129.65M | +3.3% | -51.2% |
| September 30, 2024 | -$85.73M | +10.3% | +36.3% |
| June 30, 2024 | -$134.56M | +2.4% | -0.3% |
| March 31, 2024 | -$134.11M | -15.3% | -40.3% |
| September 30, 2023 | -$95.58M | +13.8% | +30.7% |
| June 30, 2023 | -$137.88M | -45.8% | -18.5% |
- ImmunityBio, Inc. showed an increase of +15.0% in Net Income compared to the prior fiscal year.
- Over the 2013–2025 period, ImmunityBio, Inc.’s net income has declined by 17066.5% (from -$2.05 million to -$351.40 million).
- The most recent figure is from ImmunityBio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: